menu
    • menu

    Company profile for Nammi Therapeutics

    NEW Drugs in Dev: 1
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Nammi Therapeutics, Inc. is an immunotherapy company developing first in class products for the treatment of cancer. Looking to extend the benefits immunotherapy to all cancer patients, Nammi has identified 3 key principles that have limited immunotherapies to date. The redundancy of immune regulatory pathways requires synergistic combinations for robust and broad efficacy. Potent immune stimulators must be dampened in circu...
    Nammi Therapeutics, Inc. is an immunotherapy company developing first in class products for the treatment of cancer. Looking to extend the benefits immunotherapy to all cancer patients, Nammi has identified 3 key principles that have limited immunotherapies to date. The redundancy of immune regulatory pathways requires synergistic combinations for robust and broad efficacy. Potent immune stimulators must be dampened in circulation to avoid systemic toxicities. Optimal therapies will employ mechanisms to selectively deliver and activate them within tumors to focus activated immune cells on killing the tumor rather than the healthy tissue.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Nammi TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    10940 Wilshire Blvd Ste 600 Los Angeles, California 90024
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.nammirx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Nammi Therapeutics Doses First Patient in QXL138AM Phase 1 Study
    Nammi Therapeutics Doses First Patient in QXL138AM Phase 1 Study

    08 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/nammi-therapeutics-inc-announces-first-patient-dosed-with-qxl138am-in-a-phase-1-study-evaluating-advanced-solid-tumors-and-multiple-myeloma-302299498.html

    PR NEWSWIRE
    08 Nov 2024
    Share Share
    Amgen & Biolabs Announce Nammi To Receive The Third Amgen Golden Ticket
    Amgen & Biolabs Announce Nammi To Receive The Third Amgen Golden Ticket

    06 Jan 2023

    // PRESS RELEASE

    https://www.amgen.com/newsroom/press-releases/2023/01/amgen-and-biolabs-la-at-the-lundquist-institute-announce-nammi-therapeutics-to-receive-the-third-amgen-golden-ticket

    PRESS RELEASE
    06 Jan 2023
    Share Share
    Nammi Therapeutics Granted FDA ODD For QXL138AM for Multiple Myeloma
    Nammi Therapeutics Granted FDA ODD For QXL138AM for Multiple Myeloma

    13 Jun 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/nammi-therapeutics-granted-fda-orphan-drug-designation-for-qxl138am-for-the-treatment-of-multiple-myeloma-301566764.html

    PRNEWSWIRE
    13 Jun 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search